• Ziarco Pharma header page image one
  • Ziarco Pharma header page image two
  • Ziarco Pharma header page image three

About Us

Ziarco is a clinical stage biotechnology company developing products to treat chronic inflammatory diseases with a focus on inflammatory skin disorders, in particular atopic dermatitis and psoriasis.

Company History

Ziarco was formed in 2012 with a portfolio of programmes from Pfizer that were in licensed with exclusive worldwide rights to the company.  The Company secured financing from world-leading investors to generate proof of concept for two compounds in three clinical studies for inflammatory skin diseases. On the 20 January 2017, Ziarco became a wholly owned subsidiary of Novartis.